A Single-dose, Randomized, Open-label, Three-period, Crossover Pharmacokinetic Study of QLC1101 in Healthy Subjects in the Fasting and Fed State
Latest Information Update: 27 May 2025
At a glance
- Drugs QLC 1101 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 27 May 2025 New trial record